UA83850C2 - Комбинация ингибитора src киназы и химиотерапевтических средств для лечения пролиферативных заболеваний - Google Patents

Комбинация ингибитора src киназы и химиотерапевтических средств для лечения пролиферативных заболеваний

Info

Publication number
UA83850C2
UA83850C2 UAA200601309A UAA200601309A UA83850C2 UA 83850 C2 UA83850 C2 UA 83850C2 UA A200601309 A UAA200601309 A UA A200601309A UA A200601309 A UAA200601309 A UA A200601309A UA 83850 C2 UA83850 C2 UA 83850C2
Authority
UA
Ukraine
Prior art keywords
treatment
combination
chemotherapeutic agents
kinase inhibitors
proliferative diseases
Prior art date
Application number
UAA200601309A
Other languages
English (en)
Ukrainian (uk)
Inventor
Френсис Уай Ф. Ли
Original Assignee
Бристол-Майэрс Сквибб Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бристол-Майэрс Сквибб Компани filed Critical Бристол-Майэрс Сквибб Компани
Publication of UA83850C2 publication Critical patent/UA83850C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
UAA200601309A 2003-07-09 2004-07-09 Комбинация ингибитора src киназы и химиотерапевтических средств для лечения пролиферативных заболеваний UA83850C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48577903P 2003-07-09 2003-07-09
PCT/US2004/021890 WO2005013983A1 (en) 2003-07-09 2004-07-09 Combination of src kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases

Publications (1)

Publication Number Publication Date
UA83850C2 true UA83850C2 (ru) 2008-08-26

Family

ID=34135068

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200601309A UA83850C2 (ru) 2003-07-09 2004-07-09 Комбинация ингибитора src киназы и химиотерапевтических средств для лечения пролиферативных заболеваний

Country Status (20)

Country Link
US (2) US20050009891A1 (ru)
EP (1) EP1643996A4 (ru)
JP (1) JP2007528849A (ru)
KR (1) KR20060032627A (ru)
CN (1) CN1849119A (ru)
AU (1) AU2004263095B2 (ru)
BR (1) BRPI0411864A (ru)
CA (1) CA2531675A1 (ru)
GE (1) GEP20094677B (ru)
IL (1) IL173008A0 (ru)
IS (1) IS8221A (ru)
MX (1) MXPA06000191A (ru)
NO (1) NO20060392L (ru)
NZ (1) NZ544587A (ru)
RS (1) RS20060011A (ru)
RU (1) RU2006103858A (ru)
TW (1) TW200505443A (ru)
UA (1) UA83850C2 (ru)
WO (1) WO2005013983A1 (ru)
ZA (1) ZA200600176B (ru)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1169038T3 (da) 1999-04-15 2012-11-26 Bristol Myers Squibb Co Cykliske proteintyrosinkinaseinhibitorer
US7491725B2 (en) 2004-02-06 2009-02-17 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
JP4879165B2 (ja) * 2004-04-20 2012-02-22 トランス テック ファーマ，インコーポレイテッド メラノコルチン受容体の調節因子としての置換チアゾール及びピリミジン誘導体
TW200628156A (en) * 2004-11-04 2006-08-16 Bristol Myers Squibb Co Combination of a SRC kinase inhibitor and a BCR-ABL inhibitor for the treatment of proliferative diseases
PE20061394A1 (es) * 2005-03-15 2006-12-15 Bristol Myers Squibb Co Metabolitos de n-(2-cloro-6-metilfenil)-2-[[6-[4-(2-hidroxietil)-1-piperazinil]-2-metil-4-pirimidinil]amino]-5-tiazolcarboxamidas
US20060235006A1 (en) * 2005-04-13 2006-10-19 Lee Francis Y Combinations, methods and compositions for treating cancer
EP1909795B1 (en) * 2005-06-09 2011-04-13 Bristol-Myers Squibb Company Pharmaceutical composition for use in treating individuals exhibiting mutant kit protein
EP1937270A1 (en) * 2005-09-21 2008-07-02 Brystol-Myers Squibb Company Oral administration of n-(2-chloro-6-methylphenyl)-2-[[6-4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-1,3-thiazole-5-carboxamide and salts thereof
US20070093499A1 (en) * 2005-10-20 2007-04-26 Bristol-Myers Squibb Company Use of dasatinib for the treatment of bone metastasis
EP1955073A2 (en) * 2005-11-15 2008-08-13 Brystol-Myers Squibb Company Methods of identifying and treating individuals exhibiting mdr-1 overexpression with protein tyrosine kinase inhibitors and combinations thereof
WO2007109527A1 (en) * 2006-03-17 2007-09-27 Bristol-Myers Squibb Company Methods of identifying and treating individuals exhibiting mutant bcr/abl kinase polypeptides
EP2120964A2 (en) * 2006-12-15 2009-11-25 Abraxis BioScience, Inc. Triazine derivatives and their therapeutical applications
GB0625691D0 (en) * 2006-12-22 2007-01-31 Astrazeneca Ab Combination product
CN101265275B (zh) * 2007-02-16 2012-09-05 中国医学科学院药物研究所 4-{6-[5-(2-氯-6-甲基苯胺甲酰基)-噻唑-2-氨基]-2-甲基嘧啶-4}-哌嗪-1-磷酸二乙酯
WO2010014784A2 (en) 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
CA2731442A1 (en) * 2008-08-29 2010-03-04 Transtech Pharma, Inc. Substituted aminothiazole derivatives, pharmaceutical compositions, and methods of use
PL2769737T3 (pl) * 2009-07-20 2017-08-31 Bristol-Myers Squibb Company Kombinacja przeciwciała anty-ctla-4 z etopozydem w leczeniu synergicznym chorób proliferacyjnych
KR102427777B1 (ko) 2012-06-26 2022-08-01 델 마 파마슈티컬스 디안하이드로갈락티톨, 디아세틸디안하이드로갈락티톨, 디브로모둘시톨, 또는 그의 유사체 또는 유도체를 이용하여 유전학적 다형성이 있는 환자에 있어서 티로신-키나아제-억제제 내성 악성종양, ahi1 조절곤란 또는 돌연변이를 치료하는 방법
CN116808044A (zh) 2018-06-15 2023-09-29 汉达癌症医药责任有限公司 激酶抑制剂的盐类及其组合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5051910A (en) * 1989-10-16 1991-09-24 Honeywell Inc. Wind forecast error compensation for 4-D guidance in a aircraft flight management system
US5121325A (en) * 1990-04-04 1992-06-09 Smiths Industries Aerospace & Defense Systems, Inc. Required time of arrival (RTA) control system
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
DK1169038T3 (da) * 1999-04-15 2012-11-26 Bristol Myers Squibb Co Cykliske proteintyrosinkinaseinhibitorer
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
US6507782B1 (en) * 2001-05-14 2003-01-14 Honeywell International Inc. Aircraft control system for reaching a waypoint at a required time of arrival
CN1523991A (zh) 2001-08-10 2004-08-25 ��˹��ŵ�� 单独的c-Src抑制剂或其与STI571的组合用于治疗白血病的用途
US20040209930A1 (en) * 2002-10-02 2004-10-21 Carboni Joan M. Synergistic methods and compositions for treating cancer
US20050215795A1 (en) * 2004-02-06 2005-09-29 Bang-Chi Chen Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
US7652146B2 (en) * 2004-02-06 2010-01-26 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-carboxamides useful as kinase inhibitors

Also Published As

Publication number Publication date
CN1849119A (zh) 2006-10-18
BRPI0411864A (pt) 2006-08-08
EP1643996A4 (en) 2009-06-03
NZ544587A (en) 2009-07-31
IS8221A (is) 2006-01-06
NO20060392L (no) 2006-02-03
JP2007528849A (ja) 2007-10-18
EP1643996A1 (en) 2006-04-12
US7622472B2 (en) 2009-11-24
RS20060011A (en) 2007-12-31
US20080153842A1 (en) 2008-06-26
IL173008A0 (en) 2006-06-11
US20050009891A1 (en) 2005-01-13
TW200505443A (en) 2005-02-16
CA2531675A1 (en) 2005-02-17
WO2005013983A1 (en) 2005-02-17
AU2004263095B2 (en) 2009-10-29
MXPA06000191A (es) 2006-04-11
KR20060032627A (ko) 2006-04-17
RU2006103858A (ru) 2006-06-27
ZA200600176B (en) 2010-06-30
AU2004263095A1 (en) 2005-02-17
GEP20094677B (en) 2009-05-10

Similar Documents

Publication Publication Date Title
NO20060392L (no) Kombinasjon av SRC kinase inhibitorer kemoterapeutiske midler for behandling av proliferative sykdommer
PL368973A1 (en) Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
HK1092467A1 (en) N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses n-
TW200801008A (en) Protein kinase inhibitors
TW200628156A (en) Combination of a SRC kinase inhibitor and a BCR-ABL inhibitor for the treatment of proliferative diseases
TW200604192A (en) Compounds and methods for inhibiting mitotic progression
WO2006024018A3 (en) Compositions for treating nociceptive pain
WO2007064797A3 (en) Inhibitors of c-met and uses thereof
EP1622589A4 (en) COMPOSITIONS, TARGETS, METHODS AND DEVICES FOR THE TREATMENT OF OCULAR AND PERIOCULAR DISORDERS
EA025871B9 (ru) Ингибиторы mek и способы их применения
MX2009006627A (es) Quinazolinas para la inhibicion de pdk1.
TW200510416A (en) P38 inhibitors and methods of use thereof
TW200720272A (en) Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders
WO2005048953A3 (en) Amide derivatives as kinase modulators
WO2006031806A3 (en) 2-thiopyrimidinones as therapeutic agents
WO2001044247A3 (en) Agents and methods for the treatment of proliferative diseases
WO2007050793A3 (en) Methods and compositions for the treatment of marfan syndrome and associated disorders
IL195217A0 (en) Protein kinase inhibitors and uses thereof
UA84929C2 (en) Prodrugs of pyrrolylpyrimidine erk protein kinase inhibitors
MX2009002842A (es) Inhibidores heterociclicos de c-met y usos de los mismos.
WO2005092062A3 (en) Compounds for neurodegenerative disorders
WO2004009609A3 (en) Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations
TW200508233A (en) Chk-1 inhibitors
TW200716561A (en) P38 inhibitors and methods of use thereof
WO2006128120A3 (en) Novel lapachone compounds and methods of use thereof